Purpose: Newer antiepileptic drugs (AEDs), such as Eslicarbazepine (ESL), Lacosamide (LAC), Perampanel (PER) and Brivaracetam (BRV), have been marketed as adjunctive treatments for partial-onset seizures. Our aim was to compare the efficacy and tolerability of newer AEDs with Levetiracetam (LEV), when used as add-on treatments for uncontrolled focal epilepsy. Method: We conducted an online database search on PubMed, Embase, Cochrane Online Library and Clinicaltrials.gov for all available randomized controlled trials (RCTs) investigating the therapeutic effects of newer AEDs or LEV vs placebo. Indirect comparisons for clinical efficacy and tolerability at different doses between the newer AEDs and LEV were then performed using Indirect Treatment Comparison (ITC) software. Results: Twenty-four RCTs with a total of 8540 patients were included. Compared to LEV, ESL, LAC and BRV did not showed significant difference in efficacy at all dose level. PER showed lower 50% response rates and seizure-free rates at the highest effective recommended dosages. Treatment-emergent adverse events (TEAEs) and withdrawal rates due to adverse events (AEs) of LAC and PER were higher than LEV at the highest effective recommended dosages, and overall AE rates from ESL were higher than LEV. Conclusions: Indirect comparisons suggested that ESL, LAC and BRV were not inferior to LEV in efficacy. ESL, LAC and PER may have a possible worse tolerability profile compared to LEV at high dose. But BRV may exhibit a similar tolerability to LEV. Newer AEDs cannot exceed the LEV on efficacy and tolerability.
Introduction
Epilepsy is one of the most common neurological diseases. Up to 30% of patients ultimately develop refractory epilepsy despite appropriate medical therapy [1] . In recent years, a number of newer AEDs with more desirable safety profiles have been introduced on the market to offer better seizure control for patients with epilepsy, especially for those with refractory epilepsy. Consequently, add-on therapy with newer AEDs is now considered an important choice for patients with refractory epilepsy [2] . Many randomized controlled trials (RCTs) have shown that the newer AEDs offer better seizure control than placebo when used as an adjunctive treatment for patients with partial-onset seizure. Due to the relatively small number of enrolled participants in individual studies and the lack of head-tohead comparisons between these newer drugs, it is still uncertain whether the claimed efficacy and safety of these latest AEDs can exceed those have already been wildly prescribed. Levetiracetam (LEV) is one of the most commonly used AEDs in clinical which have good efficacy and tolerability when applied to treat focal seizures [3] . However, no RCT has been performed that directly compares the efficacy of these newer AEDs with LEV when used as an add-on treatment for uncontrolled focal epilepsy. We conducted an indirect-comparison meta-analysis to ascertain whether the newer AEDs are more effective and safer than LEV.
Methods

Data sources and search
We searched online databases including PubMed, Embase, Cochrane Online Library, and Clinicaltrials.gov. Last search was performed on 31st May 2017. Search terms included:,epilepsy, placebo, randomi*, with one or more of the following AEDs: Eslicarbazepine (ESL), Lacosamide (LAC), Perampanel (PER), Brivaracetam (BRV), or Levetiracetam (LEV). Two reviewers independently reviewed the titles and abstracts from the search results for any article that was potentially relevant. Published trials without articles were also evaluated based on the summary of information available online.
Study selection
The two reviewers independently assessed the eligibility of potentially relevant studies according to predefined inclusion criteria. Disagreements were resolved by consensus between investigators.
Inclusion criteria:
1. Study design: randomized, double-blind, placebo-controlled trials evaluating ESL, LAC, PER, BRV or LEV vs. placebo as an addon treatment for uncontrolled focal epilepsy. 2. Population: Adult participants who were diagnosed with partial-onset epilepsy according to the guideline of International League Against Epilepsy (ILAE) and have failed at least one to two kinds of AEDs. 3. Outcomes: all data had to come from full journal publications or summaries of clinical trial reports; at least one of the following data must be provided by the included studies: 50% responder rates, seizure-free rates, proportion of patients with any treatment emergent adverse event (TEAEs), withdrawal rates due to adverse events (AEs) and serious adverse events (SAEs)
Data extraction and evaluation of evidence
Two reviewers independently extracted relevant information from each eligible study using a data extraction form that included study design, inclusion criteria of patients, drug dosage(s), number of patients (intent-to-treat[ITT]), gender, age, duration of epilepsy, titration, concomitant AEDs at baseline, study duration, seizure types, 50% responder rate, seizure-free rates, TEAEs, withdrawal rates due to AEs, and SAEs. The bias of included studies was assessed using the guideline for assessing risk of bias in the Cochrane handbook 5.1.0 [4] . Any discrepancies between the two independent reviewers were resolved by consensus between investigators.
Outcome measures
To measure the efficacy of the newer AEDs compared to LEV, 50% responder rates and seizure-free rates during the treatment period were evaluated; 50% responder rates was defined as the proportion of patients with 50% or greater reduction in seizure frequency during the treatment period compared to the prerandomization baseline period. Proportion of patients with any treatment-emergent adverse event (TEAEs), withdrawal rates due to AEs and proportion of patients with SAEs were used to measure tolerability of the newer AEDs compared to LEV. TEAEs was an adverse events occurring after the first intake of study treatment in the double-blind phase, in each group; SAEs were defined as AEs were life-threatening, which can result in death, a persistent or significant disability, a congenital birth defect, or hospitalization.
Data analysis
All statistical analyses were performed using Review Manager 5.3 (Cochrane Collaboration) and ITC software (Canadian Agency for Drugs and Technologies in Health, Indirect Treatment Comparison software, Ottawa, Ontario, Canada). For dichotomous variables, we calculated risk differences (RDs) as statistical value with 95% confidence interval (CI). Mantal-Haenszel model were applied in meta-analysis. Statistical heterogeneity was assessed using the I 2 test. Fixed effect models were applied for comparisons with I 2 < 50%, and the randomized effect model was used for comparisons with I 2 ! 50% [5] . We performed conventional metaanalyses comparing the 50% responder rates and seizure-free rates of all newer AEDs and LEV against placebo in patients with uncontrolled focal epilepsy. Because no published studies have compared newer AEDs with LEV directly, we were unable to use weighted methods to estimate RDs. Therefore, we performed an indirect comparison for newer AEDs against LEV in patients with uncontrolled focal epilepsy using ITC software. A common reference-based indirect comparison meta-analysis is a method of synthesizing data from different interventions. For example, if we try to compare A with B indirectly, direct evidence should be provided by studies that compare A with C and B with C, respectively. Thus, by statistical calculation indirect evidence is available for comparison on A with B mediated by C. The Bucher approach was applied in our indirect comparisons [6] . The indirect comparison of newer AEDs with LEV was mediated by placebo. For performing indirect comparison meta-analysis, we adopted the framework for assessing exchangeability assumption proposed by ICWG to investigate whether these included studies were systematically similar [7] .
Considering that there are differences in efficacy and tolerability to the AEDs at different doses, apart from comparing them at all doses combined, comparisons were also made between the minimum effective daily doses, and the highest effective recommended doses, using the summaries of the product characteristics for each drug as approved by the European Medicines Agency and the Food and Drug Administration [8] [9] [10] [11] [12] and which was accordance with two previous studies [13, 14] : the minimum effective recommended daily doses (ESL 800 mg, LCM 200 mg, PER 8 mg, or BRV 50 mg versus LEV1,000 mg) and the highest effective recommended daily doses (ESL 1200 mg, LCM 400 mg, PER 12 mg or BRV 200 mg versus LEV 3000 mg).
Taking potential source of heterogeneity into account, we performed two sensitivity analyses: first by removing the studies with small sample size and second by including only RCTs where responder rates were calculated by comparing seizure frequency during baseline with that during the maintenance period.
Results
Study selection
Clinical trial databases were searched for RCTs that had been published. This search yielded 222 papers in PubMed, 471 in EMBASE, 204 in Cochrane Online Library, and 157 in clinicaltrials. gov. After an initial screening, non-randomized, trials using other AED as control as well as studies performed on children, healthy volunteers, or for indications other than epilepsy were excluded. Twenty-seven papers were identified. One RCT evaluating monotherapy using LEV was excluded [15] . To reduce methodological heterogeneity across trials, we excluded one RCT administering flexible-dose of BRV [16] . In one study on ESL [17] , we only included participants who took ESL once daily because all other studies were designed to administer ESL once daily. Twenty-five randomized, placebo-controlled, double-blind trials (5 with ESL, 4 with LCM, 4 with PER, 5 with BRV, and 7 with LEV) were included in our final analysis . A flowchart detailing the study selection process is shown in Fig. 1. 
Characters of included studies
The twenty-five selected studies included a total of 8540 patients, 4986 of whom were randomized to the newer AEDs treatment, 948 to LEV treatment, and 2696 to placebo. The overall characteristics of these trials were suitably similar.
Characteristics of the included studies are summarized in Table 1 .
Risk of bias in included studies
According to the Cochrane Handbook of Systematic Review, random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting are considered when assessing bias. All included studies had either low or unclear bias risks. Random sequence generation was described in most studies [18] [19] [20] [21] 23, 24, [27] [28] [29] 32, 33, 35, 40, 41] but some [22, 25, 26, 30, 31, 34, [36] [37] [38] [39] didn't give sufficient information about the sequence generation process. Allocation concealment was completed by clearly described methods in nine studies [21, [27] [28] [29] [30] 34, 35, 40, 41] and the outcome measurement was not likely to be influenced by lack of blinding in eleven studies [18, 21, 22, [27] [28] [29] [30] 34, 35, 40, 41] , which we rated as low risk. However, others have insufficient information to make certain judgments. Incomplete outcome data and selective reporting were considered low in all studies, except one with high proportion of missing data without appropriate reasons [17] . Details on the risk of bias for the included studies are provided as Supplementary material.
Conventional meta-analysis per AED
The RDs of efficacy in newer AEDs or LEV treatment vs. placebo are depicted in Table 2 . Most of newer AEDs showed significant higher rate in 50% responder rate and seizure-free rate compared to placebo at all dose level. Only seizure free rates at the minimum effective daily doses for LAC and BRV, and the highest effective recommended dose for PER did not reach statistical significance over placebo.
The RDs of tolerability in newer AEDs or LEV treatment vs. placebo patients are depicted in Table 2 . We did not find significant differences in TEAEs, withdrawal rates due to AEs and SAEs in all dose levels compared to placebo for BRV and LEV, except for withdrawal due to AEs at all doses combined on LEV. For ESL, statistically significant differences in TEAEs and withdrawal rates due to AEs were found in all dose levels compared to placebo. LAC showed higher risk of TEAEs, withdrawal rates due to AEs and SAEs at the highest effective recommended dose. PER also had higher risk of TEAEs and withdrawal rates due to AEs at the highest effective recommended daily dosages and at all doses combined.
3.5. Common reference-based indirect comparisons 3.5.1. 50% responder rates The RDs of 50% responder rates between ESL, LAC, PER, or BRV vs LEV at different dose level are depicted in Table 3 . Common reference-based indirect comparisons by combining meta-analyses of AEDs showed that the 50% responder rates of patients with uncontrolled focal epilepsy were significantly lower for PER 12 mg compared to LEV 3000 mg [RD À0.12,95%CI (À0.223, À0.017)] (Table 3A) .
Seizure freedom
In our study, indirect comparisons showed seizure-free rates for patients with uncontrolled focal epilepsy was significantly lower for PER compared to LEV at the highest effective recommended daily dosages [RD À0.05,95% CI (À0.093, À0.007)] and at all doses combined [RD À0.03,95% CI (À0.055, À0.005)] (Table 3B) .
Treatment-emergent adverse events
According to the indirect evidence, the risks for having TATEs were significantly higher than LEV for ESL[RD 0. (Table 3C ).
Withdrawal rates due to AEs
Our indirect comparison demonstrated that there were significantly higher risks of AEs for those taking ESL [RD 0. (Table 3D) .
SAEs
Common reference-based indirect comparisons by combining meta-analyses of AEDs suggested that the risk of experiencing SAEs did not differ from ESL, LAC, PER, or BRV to LEV at the minimum, the highest effective recommended daily dosages or at all doses combined (Table 3E) .
Sensitivity tests
We conducted two sensitivity tests on our results. First, we removed two small sample size studies with less than 50 patients in the treatment group from the analysis [40, 41] . The second sensitivity analysis included only the RCTs [18, 19, 21, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] in which the 50% responder rates was defined as the number of patients who experienced a reduction in seizure frequency of at least 50% from baseline to maintenance. The results were demonstrated in Table 4 . ÃIn the ESL 1200 mg group, patients had a 2-week titration period before reaching the full maintenance dose of 1200 mg. 
Discussion
This study compared the efficacy and tolerability between newer AEDs and LEV when used as add-on treatment in patients with uncontrolled focal epilepsy by evaluating twenty-five randomized placebo-controlled studies. To our knowledge, this is the first meta-analysis that aimed to compare new generation antiepileptic drugs to the one of the most widely applied antiepileptic drugs, LEV [42, 43] .
The validity of indirect comparisons depends on the similarity of the RCTs and the methodological quality of the individual studies being compared [44] . We strictly predefined inclusion criteria to ensure study designs and populations were similar. All patients were adults with focal epilepsy uncontrolled by one or more AEDs. None of studies had high risk of selection bias, performance bias, or detection bias. Therefore, included studies were overall clinically and methodologically homogeneous.
In direct comparisons, it was proposed by some studies that OR would be more widely accepted as statistical value [14, 45] . Thus, we provided the results of our study in ORs as Supplementary material.
Comparing to LEV, PER was less efficacious both in terms of 50% responder rates and rates of seizure freedom at the highest effective recommended daily dosages. However, ESL, LAC and BRV were not inferior to LEV in either 50% responder rates or seizure freedom rates at all dose levels. There was a trend toward better efficacy for LEV versus any of the newer AEDs because the RDs at all dose levels were >0. These findings are consistent with those of a recent study [46] . However, it is known that responder rates have been increased over the years both for AEDs and for placebo and this may make it difficult to demonstrate a significant difference over placebo in most recent RCTs, which may explain the better results towards LEV over the newest AED [47] . To be notices, the calculation of responder rate was inconsistent: either by comparing seizure frequency during baseline with that during the maintenance period or with that during the entire double-blind period (titration and maintenance). Because these two different methods of defining responder rate might be a possible source of methodological heterogeneity, we conducted a sensitivity analysis on 50% responder rate by including only RCTs calculating responder rate in the maintenance period compared to baseline. No significant changes were observed from the main analysis. We also excluded studies with small sample size. There are barely no significant changes in efficacy from this sensitivity test, except that BRV showed lower 50% responder rate than LEV at the highest effective recommended daily dosages.
The overall rates of adverse effect from ESL were disappointingly higher than that of LEV, which was also shown in a previous study [48] . Our results also suggested a possible worse tolerability profile of high dose LAC and PER compared to high dose LEV. Finally, BRV exhibited a similar tolerability to LEV. In the two sensitivity tests mentioned above, there were no significant changes in the main results. As is known, some neurological AEs (ataxia, dizziness, etc) are frequently associated with AEDs acting on voltage-gated sodium channels [49] , such as ESL and LAC, which may appear at high doses or with a short titration. However, with its novel mechanism, AEs of LEV might not be that dosedependent. Also, the relatively short observation periods of these studies might fail to reveal long-term AEs. However, in our study we didn't compare the specific AEs, such as anxiety, depression, etc, which might be different between the newer AEDs and LEV, thus further study are still needed. Therefore, these results nonetheless need to be confirmed by future prospective headto-head RCTs.
There are other potentially confounding factors that may also have contributed to or attenuated our findings. There were some differences between the populations of patients included in the different studies. In studies involving the newer AEDs, some patients concomitantly used LEV, indicating that LEV alone did not provide adequate seizure control for those patients. Consequently, when the newer AEDs were added to treat patients who were not well controlled by LEV, they may show lower efficacy. Secondly, the efficacy and tolerability of the newer AEDs may be affected by the fact that they were used as add-on treatment for patients with uncontrolled focal epilepsy who were already using another AED. For example, previous studies have suggested that BRV may have reduced efficacy in patients taking concomitant LEV [32, 33] .
Our findings suggested that even though large scale of investment has been put into the development of new AEDs, the outcome was somehow disappointing. According to our study, new AEDs did not show significant superiority over LEV on efficacy. On the other hand, their chance for leading to adverse events was somehow higher than LEV. On a larger scale, latest study implied that even thought we witnessed quite a few new AEDs putting into the market, the proportion of drug resistant epilepsy patients in all epilepsy population did not change significantly [50] . Currently developed newer AEDs mostly origin from chemical compounds which have anticonvulsive effects on induced seizure models, but not real epilepsy models [51] . Since the epileptic network does not exist in induced seizure models, the development of these so called 'new' AEDs might already be failed at the beginning. Our current understanding for the mechanism behind drug resistant epilepsy is very limited, which could somehow explain their ineffectiveness in drug resistant patients with epilepsy. Much attention should be paid to explore the potential mechanism for AEDs in drug-resistant patient. Also, precision medicine could benefit patients in controlling drug resistant epilepsy.
There are still some limitations to our analysis. Firstly, our results were based on indirect comparison, not on a direct, randomized-controlled, double-blinded clinical study directly comparing the newer AEDs and LEV, which may lead to possible biases on study design. Therefore, indirect studies provide more uncertainty than direct comparisons. Secondly, the RCTs included in our analysis all had short study durations; additional RCTs are needed that investigate the long-term efficacy and tolerability of newer AEDs and LEV as add-on therapy. Thirdly, the numbers of participants in the RCTs included in this meta-analysis were relatively small; further RCTs with larger sample sizes are needed to support these findings.
Conclusion
This meta-analysis suggested that among the newer AEDs, ESL, LAC and BRV were not inferior to LEV in efficacy, but PER may be less efficacious at the highest effective recommended daily dosages compared to LEV. A possible worse tolerability profile of ESL, LAC and PER compared to LEV at high dose was found. BRV exhibited a similar tolerability to LEV. The results from these indirect comparisons should be verified and confirmed through future well-designed clinical trials.
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